Aurinia Pharmaceuticals Inc. (AUPH)
NGM · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
April 2026
Aurinia Pharmaceuticals Inc. — 8-K Filing
# 🧾 What This Document Is This is an **8-K filing**, which companies use to announce major events to investors. This specific filing reports that **Aurinia Pharmaceuticals (AUPH)** is acquiring **Kezar Life Sciences**. It includes the signed legal agreements that officially start the buyout process
SEC filings
All filings →Insider trades
All insider trades →Aurinia Pharmaceuticals Inc. has no reported insider trades in the last 90 days.